Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SAVA Cassava Sciences Inc

Post-Market Trading 11-21 18:21:13 EST

32.18

+6.13

+23.53%

盘后32.86

+0.68+2.11%

18:20 EST

High33.98	Low26.03	Vol4.63M
Open26.13	D1 Closing26.05	Amplitude30.52%
Mkt Cap1.55B	Tradable Cap1.38B	Total Shares48.11M
T/O143.47M	T/O Rate10.79%	Tradable Shares42.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SAVA","market":"US","secType":"STK","nameCN":"Cassava Sciences Inc","latestPrice":32.18,"timestamp":1732222800000,"preClose":26.05,"halted":0,"volume":4633352,"hourTrading":{"tag":"盘后","latestPrice":32.86,"preClose":32.18,"latestTime":"18:20 EST","volume":19022,"amount":619075.821588,"timestamp":1732231207831},"delay":0,"floatShares":42925070,"shares":48110475,"eps":-1.37344,"marketStatus":"Post-Market Trading","change":6.13,"latestTime":"11-21 18:21:13 EST","open":26.13,"high":33.98,"low":26.03,"amount":143467908.264544,"amplitude":0.305182,"askPrice":32.99,"askSize":20,"bidPrice":32.8,"bidSize":650,"shortable":3,"etf":0,"ttmEps":-1.37344,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732237200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":26.05,"preHourTrading":{"tag":"盘前","latestPrice":26.53,"preClose":26.05,"latestTime":"09:28 EST","volume":16668,"amount":443336.447412,"timestamp":1732199308043},"postHourTrading":{"tag":"盘后","latestPrice":32.86,"preClose":32.18,"latestTime":"18:20 EST","volume":19022,"amount":619075.821588,"timestamp":1732231207831},"volumeRatio":2.504443,"impliedVol":4.7535,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/SAVA","defaultTab":"news","newsList":[{"id":"2484663672","title":"Cassava Sciences put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2484663672","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484663672?lang=en_us&edition=fundamental","pubTime":"2024-11-18 23:35","pubTimestamp":1731944105,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Cassava Sciences (SAVA) with 3,180 puts trading, or 1.8x expected. Most active are 11/22 weekly 13 puts and 11/22 weekly 25 p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cassava-sciences-put-volume-heavy-and-directionally-bearish-11?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cassava-sciences-put-volume-heavy-and-directionally-bearish-11?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4547","BK4007","BK4588","SAVA"],"gpt_icon":0},{"id":"2484965055","title":"Cassava taps Freda Nassif as chief commercial officer as simufilam Phase 3 readout nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2484965055","media":"seekingalpha","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484965055?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:10","pubTimestamp":1731939028,"startTime":"0","endTime":"0","summary":"SAVA shares were up 3% premarket.","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518929263/image_518929263.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518929263/image_518929263.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4302164-cassava-taps-freda-nassif-as-chief-commercial-officer-as-simufilam-phase-3-readout-nears","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4533","IE00B19Z3581.USD","LU0868494617.USD","SG9999001176.SGD","LU0306807586.USD","LU0234572021.USD","SG9999002224.SGD","LU1894683264.USD","SG9999003800.SGD","LU0985481810.HKD","LU0321505439.SGD","LU0321505868.SGD","LU0456855351.SGD","BK4592","BK4534","SAVA","LU1057294990.SGD","PFE","BK4585","LU1066051498.USD","SG9999002232.USD","IE0002270589.USD","LU0058720904.USD","SG9999001176.USD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU1894683348.USD","BK4588","LU0225284248.USD","BK4007","BK4550","IE00BBT3K403.USD","BK4547","LU0122379950.USD","SGXZ57979304.SGD","LU1066053197.SGD","LU1023059063.AUD","LU0170899867.USD","BK4568","LU0225771236.USD","LU1883839398.USD","LU0306806265.USD","SG9999011175.SGD","IE00BLSP4239.USD","SG9999013999.USD","LU0289739699.SGD","IE00BLSP4452.SGD","BK4581"],"gpt_icon":1},{"id":"2484062002","title":"BRIEF-Cassava Sciences Appoints Freda Nassif As Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2484062002","media":"Reuters","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484062002?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:48","pubTimestamp":1731937738,"startTime":"0","endTime":"0","summary":"BRIEF-Cassava Sciences Appoints Freda Nassif As Chief Commercial OfficerNov 18 (Reuters) - Cassava Sciences Inc SAVA.O:CASSAVA SCIENCES APPOINTS FREDA NASSIF AS CHIEF COMMERCIAL OFFICERCASSAVA SCIENCE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUABJ51FT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","BK4547","SAVA","BK4585"],"gpt_icon":0},{"id":"2484620994","title":"Cassava Sciences appoints Freda Nassif as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2484620994","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484620994?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:40","pubTimestamp":1731937215,"startTime":"0","endTime":"0","summary":"Cassava Sciences (SAVA) announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. “I am thrilled to expand Cassava’s ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cassava-sciences-appoints-freda-nassif-as-chief-commercial-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cassava-sciences-appoints-freda-nassif-as-chief-commercial-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4007","BK4547","BK4585","SAVA"],"gpt_icon":0},{"id":"2484627291","title":"Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2484627291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484627291?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:30","pubTimestamp":1731936602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUABJ51FT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4547","BK4007","BK4588","SAVA"],"gpt_icon":0},{"id":"2484627229","title":"Cassava Sciences Inc: First Phase 3 Topline Data Readout Before Year End 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484627229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484627229?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:30","pubTimestamp":1731936602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUABJ51FT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4007","SAVA","BK4588","BK4585"],"gpt_icon":0},{"id":"2484962726","title":"Press Release: Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2484962726","media":"Dow Jones","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484962726?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:30","pubTimestamp":1731936600,"startTime":"0","endTime":"0","summary":"Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs. Appointment initiates Cassava's commercial readiness strategy as the Company prepares for. AUSTIN, Texas, Nov. 18, 2024  -- Cassava Sciences, Inc. , a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. As a member of the Company's executive leadership team, Ms. Nassif will report to Richard \"Rick\" Barry, President and Chief Executive of Cassava.Freda Nassif, Chief Commercial Officer of Cassava commented, \"I am honored to have the opportunity to lead the commercial organization for a novel therapy at a time in which there are unprecedented challenges for people living with Alzheimer's Disease. Developing innovative commercial strategies has been the focus of my career and I look forward to bringing my experience to a com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","SG9999003800.SGD","IE00B19Z3581.USD","LU0456855351.SGD","LU1023059063.AUD","IE00BLSP4452.SGD","SAVA","LU0306806265.USD","SG9999001176.USD","LU0225771236.USD","BK4550","LU0306807586.USD","LU0234572021.USD","SGXZ57979304.SGD","LU1894683348.USD","R","LU1883839398.USD","PFE","LU0058720904.USD","BK4534","LU0122379950.USD","BK4547","LU1894683264.USD","BK4007","BK4022","BK4533","LU1057294990.SGD","LU0289739699.SGD","BK4585","SG9999002224.SGD","SG9999002232.USD","LU0321505439.SGD","BK4232","IE00B19Z3B42.SGD","BK4588","IE0002270589.USD","SG9999011175.SGD","LU0170899867.USD","SG9999013999.USD","IE000M9KFDE8.USD","LU0985481810.HKD","LU1066053197.SGD","BK4581","LU0321505868.SGD","LU0868494617.USD","LU0225284248.USD","BK4568","SG9999001176.SGD","IE00BLSP4239.USD"],"gpt_icon":1},{"id":"2483158925","title":"Cassava Sciences call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2483158925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483158925?lang=en_us&edition=fundamental","pubTime":"2024-11-16 03:11","pubTimestamp":1731697867,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Cassava Sciences (SAVA) with 8,785 calls trading, 1.9x expected, and implied vol increasing over 34 points to 441.6...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cassava-sciences-call-volume-above-normal-and-directionally-bullish-38?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cassava-sciences-call-volume-above-normal-and-directionally-bullish-38?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","SAVA","BK4007","BK4588","BK4547"],"gpt_icon":0},{"id":"2483583790","title":"Cassava Sciences updates on Phase 3 Alzheimer’s trial ahead of key readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2483583790","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483583790?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:17","pubTimestamp":1731687433,"startTime":"0","endTime":"0","summary":"travellinglight/iStock via Getty Images A federal registry on clinical trials indicated on Friday that Cassava Sciences (NASDAQ:SAVA) had completed its Phase 3 RETHINK-ALZ trial for its Alzheimer’s ca","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518929263/image_518929263.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518929263/image_518929263.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4295466-cassava-sciences-stock-alzheimers-update","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["QID","BK4007","SAVA","NQmain","MNQmain","TQQQ","SQQQ",".IXIC","BK4547","QLD","BK4588","BK4585","PSQ"],"gpt_icon":0},{"id":"2483041323","title":"Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2483041323","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483041323?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:40","pubTimestamp":1731681610,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Cassava Sciences, Inc.  is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole?By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Cassava Sciences, Inc. is one of 1024 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. C","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aMCT_Lh5K9xNn9.QUdX03w--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aMCT_Lh5K9xNn9.QUdX03w--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-sava-outperforming-other-144010455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SAVA","SAVAW"],"gpt_icon":0},{"id":"2482883755","title":"Cassava Sciences call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2482883755","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482883755?lang=en_us&edition=fundamental","pubTime":"2024-11-12 01:35","pubTimestamp":1731346525,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Cassava Sciences (SAVA) with 4,488 calls trading, 1.2x expected, and implied vol increasing almost 28 points to 375...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cassava-sciences-call-volume-above-normal-and-directionally-bullish-36?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cassava-sciences-call-volume-above-normal-and-directionally-bullish-36?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4585","SAVA","BK4547","BK4588"],"gpt_icon":0},{"id":"1192356244","title":"Stock Track | Cassava Sciences Soars on Positive Analyst Outlook for Alzheimer's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1192356244","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192356244?lang=en_us&edition=fundamental","pubTime":"2024-11-09 03:44","pubTimestamp":1731095086,"startTime":"0","endTime":"0","summary":"Shares of Cassava Sciences Inc.  soared by 5.05% on Thursday, November 8th, 2024, closing at $116 per share. The surge was primarily driven by a positive analyst rating and price target from H.C. Wainwright.H.C. Wainwright analyst Vernon Bernardino maintained a Buy rating on Cassava Sciences and set a price target of $116 for the stock. Bernardino's bullish outlook was based on the promising potential of Cassava's investigational drug simufilam as a disease-modifying treatment for Alzheimer's di","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Cassava Sciences Soars on Positive Analyst Outlook for Alzheimer's Drug","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SAVA"],"gpt_icon":0},{"id":"2482632432","title":"Cassava Sciences Price Target Maintained With a $116.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2482632432","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482632432?lang=en_us&edition=fundamental","pubTime":"2024-11-09 03:38","pubTimestamp":1731094680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SAVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 08, 2024 14:38 ET (19:38 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAVA"],"gpt_icon":0},{"id":"2481617959","title":"Cassava Sciences’ Simufilam Shows Promise as Disease-Modifying Alzheimer’s Treatment Amid Positive Phase 3 Trial Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2481617959","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481617959?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:15","pubTimestamp":1731068135,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Vernon Bernardino maintained a Buy rating on Cassava Sciences (SAVA – Research Report) today and set a price target of $116...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cassava-sciences-simufilam-shows-promise-as-disease-modifying-alzheimers-treatment-amid-positive-phase-3-trial-expectations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cassava-sciences-simufilam-shows-promise-as-disease-modifying-alzheimers-treatment-amid-positive-phase-3-trial-expectations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","BK4007","SAVA","BK4588","BK4585"],"gpt_icon":0},{"id":"2481461491","title":"Cassava Sciences: With Almost Half The Float Shorted, Results Could Be Interesting","url":"https://stock-news.laohu8.com/highlight/detail?id=2481461491","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481461491?lang=en_us&edition=fundamental","pubTime":"2024-11-08 15:33","pubTimestamp":1731051187,"startTime":"0","endTime":"0","summary":"Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.The bull thesis hinges on simufilam outperforming current treatments or showin","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/88621226/image_88621226.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/88621226/image_88621226.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4734790-cassava-sciences-almost-half-float-shorted-results-be-interesting","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4585","BK4547","BK4007","BK4588","SAVA"],"gpt_icon":0},{"id":"2481116033","title":"Cassava Sciences’ Q3 2024: Financials and Alzheimer’s Trials Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2481116033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481116033?lang=en_us&edition=fundamental","pubTime":"2024-11-08 13:57","pubTimestamp":1731045425,"startTime":"0","endTime":"0","summary":"Cassava Sciences ( ($SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors. Cass...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cassava-sciences-q3-2024-financials-and-alzheimers-trials-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cassava-sciences-q3-2024-financials-and-alzheimers-trials-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","BK4588","BK4007","BK4547","LU2065732104.USD","BK4585","PRGS","SAVA"],"gpt_icon":0},{"id":"1120566228","title":"Stock Track | Cassava Sciences Stock Dips Despite Q3 Beat as Investors Await Key Alzheimer's Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1120566228","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120566228?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:26","pubTimestamp":1730993166,"startTime":"0","endTime":"0","summary":"Shares of Cassava Sciences Inc  fell 5.08% on Tuesday, despite the clinical-stage biotech company reporting better-than-expected third quarter financial results. The stock drop likely reflects investor caution ahead of a highly anticipated readout from Cassava's Phase 3 trial for its lead Alzheimer's drug candidate, simufilam.For the quarter ended September 30, 2024, Cassava posted a net loss of $27.9 million, or $0.58 per share, beating analysts' consensus estimate of a $0.88 per share loss. Wh","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SAVA"],"gpt_icon":0},{"id":"2481185666","title":"Cassava Sciences Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481185666","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481185666?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:29","pubTimestamp":1730989746,"startTime":"0","endTime":"0","summary":"* Cassava Sciences Inc    reported a quarterly adjusted loss of 58 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -61 cent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAVA"],"gpt_icon":0},{"id":"2481186849","title":"Cassava Sciences beats in Q3 ahead of key Alzheimer’s readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2481186849","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481186849?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:53","pubTimestamp":1730987617,"startTime":"0","endTime":"0","summary":"travellinglight/iStock via Getty ImagesCassava Sciences (NASDAQ:SAVA) reported better-than-expected earnings with its Q3 2024 financials on Thursday and reaffirmed its timeline to deliver a key Phase ","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518929263/image_518929263.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518929263/image_518929263.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4260798-cassava-sciences-stock-focus-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["SAVA","BK4007","BK4588","BK4547","BK4585"],"gpt_icon":0},{"id":"2481390134","title":"Cassava Sciences Q3 2024 GAAP EPS $(0.58) Beats $(0.88) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481390134","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481390134?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:59","pubTimestamp":1730984340,"startTime":"0","endTime":"0","summary":"Cassava Sciences (NASDAQ:SAVA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.88) by 34.09 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41804875/cassava-sciences-q3-2024-gaap-eps-0-58-beats-0-88-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Cassava Sciences Q3 2024 GAAP EPS $(0.58) Beats $(0.88) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAVA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cassavasciences.com","stockEarnings":[{"period":"1week","weight":0.0346},{"period":"1month","weight":-0.098},{"period":"3month","weight":-0.127},{"period":"6month","weight":0.1996},{"period":"1year","weight":0.1676},{"period":"ytd","weight":0.1573}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.1153},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.2423}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.541667,"avgChangeRate":0.155421},{"month":2,"riseRate":0.416667,"avgChangeRate":0.028198},{"month":3,"riseRate":0.458333,"avgChangeRate":0.024377},{"month":4,"riseRate":0.583333,"avgChangeRate":0.060573},{"month":5,"riseRate":0.416667,"avgChangeRate":0.028089},{"month":6,"riseRate":0.458333,"avgChangeRate":-0.016342},{"month":7,"riseRate":0.458333,"avgChangeRate":0.000768},{"month":8,"riseRate":0.48,"avgChangeRate":0.013502},{"month":9,"riseRate":0.6,"avgChangeRate":0.108222},{"month":10,"riseRate":0.4,"avgChangeRate":-0.045759},{"month":11,"riseRate":0.64,"avgChangeRate":0.024897},{"month":12,"riseRate":0.375,"avgChangeRate":0.049835}],"exchange":"NASDAQ","name":"Cassava Sciences Inc","nameEN":"Cassava Sciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cassava Sciences Inc,SAVA,Cassava Sciences Inc股票,Cassava Sciences Inc股票老虎,Cassava Sciences Inc股票老虎国际,Cassava Sciences Inc行情,Cassava Sciences Inc股票行情,Cassava Sciences Inc股价,Cassava Sciences Inc股市,Cassava Sciences Inc股票价格,Cassava Sciences Inc股票交易,Cassava Sciences Inc股票购买,Cassava Sciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}